NCI trial reported targeted agent trastuzumab and standard chemo cut risk of HER-2-positive breast cancer
On Apr. 25, 2005, the combination of the targeted agent trastuzumab (Herceptin) and standard chemotherapy cuts the risk…
Autism Speaks was founded in New York City
On Feb. 11, 2005, Autism Speaks was founded in New York City by Bob and Suzanne Wright, grandparents…
World Cancer Day was established by The World Health Organization
On Feb. 4, 2005, World Cancer Day was established by The World Health Organization. Cancer is a leading…
Smallpox appeared in the first agricultural settlements in northeastern Africa
On Jan. 8, 2005, researchers from Baylor University Medical Center reported that although the origin of smallpox is…
Biotechnology | Diagnostics | Disease | FDA | Nanotechnology | Oncology | Therapeutics
FDA approved albumin-stabilized nanoparticle formulation of paclitaxel for treatment of breast cancer
In Jan. 2005, the U.S. Food and Drug Administration (FDA) approved an albumin-stabilized nanoparticle formulation of paclitaxel (Abraxane)…
The Center for Drug Discovery was established at the University of Georgia
In 2005, The Center for Drug Discovery was established at the University of Georgia to fulfill a critical…
Genome Alberta was established
In 2005, Genome Alberta, was established in partnership with Genome Canada Industry Canada and the Province of Alberta,…
Diagnostics | Disease | NIH | Oncology
The Patient Navigator Research Program assessed impact of patient navigators
In 2005, The Patient Navigator Research Program (PNRP), a National Cancer Institute initiative, was underway to assess the…
The National Cancer Institute study determined that a new molecular test can predict the risk of breast cancer recurrence
On Dec. 10, 2004, a National Cancer Institute (NCI) supported study determined that a new molecular test done…
Biotechnology | Disease | FDA | Oncology | Therapeutics
Genentech drug Tarceva (erlotinib) was approved
On Nov. 18, 2004, the U.S. Food and Drug Administration (FDA) announced it had approved Genentech’s drug Tarceva…
Biotechnology | Disease | FDA | Oncology | Therapeutics | Women's Health
Letrozole was approved by the FDA for the adjuvant treatment of early-stage breast cancer after five years of tamoxifen therapy
On Oct. 29, 2004, the U.S. Food and Drug Administration (FDA) approved Letrozole for the extended adjuvant treatment…
The Schnitzer Investment Corporation donated nearly 20 acres of riverfront property in South Waterfront to OHSU
On Jun. 16, 2004, Portland’s Schnitzer Investment Corp. donated nearly 20 acres of land at the South Willamette…
Biotechnology | Diagnostics | Disease | Environmental | NIH | Non-Profit Research | Oncology | Therapeutics
The National Center for Vermiculite and Asbestos-Related Cancers was established
Apr. 14, 2004, the National Center for Vermiculite and Asbestos-Related Cancers was established in Michigan in response to…
OHSU School of Medicine’s Casey Eye Institute received $2.6 million to study glaucoma
On Jan. 29, 2004, researchers at Oregon Health & Science University (OHSU) School of Medicine’s Casey Eye Institute…
Biotechnology | Disease | FDA | Oncology | Therapeutics
The FDA approved oxaliplatin (Eloxatin) for use in the treatment of advanced colorectal cancer
On Jan. 9, 2004, the Food and Drug Administration (FDA) announced the approval of Sanofi’s Eloxatin (oxaliplatin) injection…
OMRF opened the state’s first small animal magnetic resonance imaging facility
In 2004, the Oklahoma Medical Research Foundation (OMRF) opened the state’s first small animal magnetic resonance imaging facility….
World’s first use of low-dose radioactive palladium ‘seeds’ was used to treat breast cancer patients at the Women’s Research Institute in Toronto
In 2004, the world’s first use of low-dose radioactive palladium ‘seeds’ as used to treat breast cancer patients…
William Hagopian launched The Environmental Determinants of Diabetes in the Young study
In 2004, William Hagopian, M.D., Ph.D., launched The Environmental Determinants of Diabetes in the Young (TEDDY) study at…
The Emergency Use Authorization program was established
In 2004, the Emergency Use Authorization (EUA) program was established in 2004, when the Project BioShield Act, among…
Women’s Health Initiative data showed women who take estrogen with hormone progestin have greater risk of developing breast cancer
In 2004, data from the Women’s Health Initiative (WHI) study show that women who take estrogen in combination…
A novel approach to treatment of solid cancers involved therapeutic agents that inhibit the generation of new blood vessels in growing tumors
On Nov. 19, 2003, a novel approach to treatment of solid cancers involved therapeutic agents that inhibit the…
OHSU researcher uncovered macular degeneration gene
On Oct. 21, 2003, scientists at Oregon Health Sciences University’s (OHSU) Casey Eye Institute announced they had found…
A clinical trial found post-menopausal survivors of early-stage breast cancer who took letrozole reduced risk of cancer recurrence
On Oct. 9, 2003, a Canadian-led international clinical trial found that post-menopausal survivors of early-stage breast cancer who…
The Scripps Research Institute announced the establishment of a major science center in Palm Beach County, Florida
On Oct. 9, 2003, The Scripps Research Institute (TSRI) announced the establishment of a major science center in…
The National Center for Research Resources awarded a $67 million grant to UGA for a Parkinson’s disease study
On Sept. 4, 2003, the National Center for Research Resources (NCCR) awarded a $6.7 million grant to the…
Results of the Prostate Cancer Prevention Trial were announced
On Jun. 24, 2003, results of the Prostate Cancer Prevention Trial (PCPT), testing the effectiveness of finasteride to…
Biotechnology | Disease | FDA | Therapeutics
Genentech drug Xolair (omalizumab) was approved
On Jun. 20, 2003, Genentech drug Xolair (omalizumab) was approved by the U. S. Food and Drug Administration…
The Curious Incident of the Dog in the Night-Time was published
On May 1, 2003, Mark Haddon’s The Curious Incident of the Dog in the Night-Time was published, allowing…
International consortium completed the Human Genome Project
On Apr. 14, 2003, The International Human Genome Sequencing Consortium, led in the U.S. the National Human Genome…
Taking daily aspirin for as little as 3 years was shown to reduce the development of colorectal polyps
On Mar. 5, 2003, taking daily aspirin for as little as 3 years was shown to reduce the…